Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px
Document › Details

Paion AG. (8/27/14). "Press Release: Abdelghani Omari Appointed as New Chief Financial Officer at Paion AG". Aachen.

Organisations Organisation Paion AG
  Group Paion (Group)
  Organisation 2 KPMG (Group)
Product Product remimazolam (CNS 7056)
Persons Person Omari, Abdelghani (Paion 201409– CFO joined 200810 as VP Finance before KPMG Cologne)
  Person 2 Hofer, Bernhard (Paion 201105–2012 CFO joined Paion Deutschland GmbH 2001 as Head Finance LEFT early 2012)
     


PAION AG, a Specialty Pharma Company (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) announces that Abdelghani Omari (37) has been appointed by the Supervisory Board as a new member of the Management Board of PAION AG and is Chief Financial Officer with effect from 1 September 2014.

Abdelghani Omari has been with PAION as Vice President Finance since October 2008 and after the departure of Bernhard Hofer as CFO in early 2012 he has taken over his duties but reporting to the management board. Mr Omari has intensively worked on the restructuring process and the repositioning of PAION AG in the last years and was responsible and involved in various capital market transactions and licensing agreements as Vice President Finance.

Prior to joining PAION AG, Abdelghani Omari held various positions at KPMG, Cologne in auditing and advisory. He studied at the University of Aachen and has a Diploma in Business Administration.

"I am delighted to win an experienced financial expert from among our ranks to the position of CFO. Mr. Omari has excellent knowledge of PAION's business model and will accompany the company in an even stronger position on the path through the Phase III program up to approval and commercialization. I wish him continued success in his new function," says Dr. Jörg Spiekerkötter, Chairman of the Supervisory Board of PAION AG.

"Since 2012, we have jointly conducted a total of seven product-related transactions and three financial market transactions. Mr Omari's entrepreneurial determination combined with the sensitivity for the respective financial risks has contributed significantly to the current position of PAION," commented Dr. Wolfgang Söhngen, CEO of PAION.


###


About PAION

PAION AG is a publicly-listed Specialty Pharma Company headquartered in Aachen, Germany with a second site in Cambridge, UK. The company has a track record in developing hospital-based treatments for which there is substantial unmet medical need. PAION's strategy is to extend its business model from a pure development company to a specialty pharmaceutical company with a focus on anaesthesia products. Remimazolam is intended to be the basis for its future marketing activities.


PAION Contact

Ralf Penner
Director Investor Relations / Public Relations
PAION AG
Martinstrasse 10-12
52062 Aachen - Germany
Phone: +49 241 4453-152
E-mail: r.penner@paion.com
www.paion.com


Disclaimer:

This release contains certain forward-looking statements concerning the future business of PAION AG. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG's management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from the Company's assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update any such forward-looking statements to reflect future events or developments.

   
Record changed: 2017-04-02

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px

More documents for Paion (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px




» top